MedPath

杭州朱养心药业有限公司

Ownership
-
Established
2001-08-17
Employees
-
Market Cap
-
Website
http://www.zuyaxi.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

32

NMPA:32

Drug Approvals

Metformin Hydrochloride and Empagliflozin Tablets（Ⅰ）

Product Name
二甲双胍恩格列净片(Ⅰ)
Approval Number
国药准字H20253754
Approval Date
Apr 1, 2025
NMPA

Metformin Hydrochloride and Empagliflozin Tablets（VI）

Product Name
二甲双胍恩格列净片(Ⅵ)
Approval Number
国药准字H20249745
Approval Date
Dec 17, 2024
NMPA

Selexipag Tablets

Product Name
司来帕格片
Approval Number
国药准字H20249721
Approval Date
Dec 10, 2024
NMPA

Selexipag Tablets

Product Name
司来帕格片
Approval Number
国药准字H20249719
Approval Date
Dec 10, 2024
NMPA

Selexipag Tablets

Product Name
司来帕格片
Approval Number
国药准字H20249720
Approval Date
Dec 10, 2024
NMPA

Apremilast Tablets

Product Name
阿普米司特片
Approval Number
国药准字H20233940
Approval Date
Jul 25, 2023
NMPA

Apremilast Tablets

Product Name
阿普米司特片
Approval Number
国药准字H20233942
Approval Date
Jul 25, 2023
NMPA

Apremilast Tablets

Product Name
阿普米司特片
Approval Number
国药准字H20233941
Approval Date
Jul 25, 2023
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字H20130010
Approval Date
Sep 15, 2022
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字H20130009
Approval Date
Sep 15, 2022
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.